Maze Therapeutics, Inc. (MAZE)

NASDAQHealth CareBiotechnologySnapshot 2026-11-04

$32.53-2.55%

Close 2026-11-05 · 1-day change

Maze Therapeutics, Inc. (MAZE) Outlook: What's Priced In | QuarterlyIQ

Investment OutlookAs of Nov 4, 2026

What could strengthen or challenge Maze Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

Matching fiscal periods, usable estimates and at least one analyst are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.

Price, analyst earnings & P/E reference

The EPS and P/E reference is not available for MAZE yet.

Measure / period	Management expectations	Analyst expectations

Management figures unavailable.

Current consensus figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Reduce operating losses toward manageable levels	Maze Therapeutics is managing to reduce its operating losses, cutting them from $36.47 million in 2025-Q2 to $26.55 million in 2026-Q1.	Intact	Operating losses worsen beyond -$26.55 million in any quarter after 2026-Q1	Operating income: $-48.035M FY2026-Q2; GAAP. Published target: Operating loss no worse than -$26.55 million in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 11, 2026-48,035,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-3.21

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Reduce operating losses toward manageable levelsOperating income: $-48.035M
Maintain stable management team and leadership confidencePublished status: Under Pressure
Stabilize or grow revenue after steep declinesDirect metric needs a verified mapping

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.0%Typical daily move · historical

Downside history

-56.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Maze Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 31, 2026

What kind of bet this is

This is speculative clinical-stage biotechnology, not an established earnings compounder. The long-term thesis is still active, with key trials reported on track, but recent financial performance is weak and overall risk is high.

What's priced into Maze Therapeutics, Inc.

The valuation evidence is mixed: one measure says MAZE is cheap versus peers, while another shows a peer premium. The expectations gap is slightly negative, and the overall priced-in tag is justified, with low flagged fragility; confidence in these signals is medium.

What the fundamentals likely do

Near term, clinical execution is progressing: MZE829’s Phase 2 results support planned pivotal trial initiation in 2027, and MZE782 trials are on track to start in 2026. Cash was about $360 million at 2026-Q1, and management expects available resources to fund operations into 2029, though that funding priority remains on watch. Weak recent performance and high industry miss risk remain concerns.

What Maze Therapeutics, Inc. hinges on

The multi-year view depends on advancing MZE829 and MZE782 trials and reaching the planned MZE829 pivotal-trial start. A guidance cut or further weakening in jobs data would add near-term pressure, while continued strong results and guidance from sector bellwethers could support sector momentum.

Bottom line

Over the next 1 to 3 years, MAZE’s thesis has clinical milestones and stated funding plans behind it, but weak recent performance and high risk leave execution as the central test. Not investment advice.

Development preview · refreshed Nov 5, 2026Open Living FV detail

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-3.22	$16,216,667	7 / 7
2026-07-25	$-3.22	$16,216,667	7 / 7
2026-07-26	$-3.22	$16,216,667	7 / 7
2026-07-27	$-3.22	$16,216,667	7 / 7
2026-07-28	$-3.19	$8,845,450	8 / 11
2026-07-29	$-3.22	$16,216,667	7 / 7
2026-07-30	$-3.19	$8,845,450	8 / 11
2026-07-31	$-3.19	$8,845,450	8 / 11
2026-08-01	$-3.22	$16,216,667	7 / 7
2026-08-02	$-3.19	$8,845,450	8 / 11
2026-08-03	$-3.19	$8,845,450	8 / 11
2026-08-04	$-3.19	$8,845,450	8 / 11
2026-08-05	$-3.19	$8,845,450	8 / 11
2026-08-06	$-3.22	$16,216,667	7 / 7
2026-08-07	$-3.22	$16,216,667	7 / 7
2026-08-08	$-3.19	$8,845,450	8 / 11
2026-08-09	$-3.22	$16,216,667	7 / 7
2026-08-10	$-3.19	$8,845,450	8 / 11
2026-08-12	$-3.22	$16,216,667	7 / 7
2026-08-13	$-3.22	$16,216,667	7 / 7
2026-08-14	$-3.22	$16,216,667	7 / 7
2026-08-15	$-3.22	$16,216,667	7 / 7
2026-08-16	$-3.22	$16,216,667	7 / 7
2026-08-17	$-3.22	$16,216,667	7 / 7
2026-08-18	$-3.22	$16,216,667	7 / 7
2026-08-19	$-3.22	$16,216,667	7 / 7
2026-08-20	$-3.21	$13,900,000	8 / 7
2026-08-21	$-3.21	$13,900,000	8 / 7
2026-08-22	$-3.21	$13,900,000	8 / 7
2026-08-23	$-3.21	$13,900,000	8 / 7
2026-08-24	$-3.21	$13,900,000	8 / 7
2026-08-25	$-3.21	$13,900,000	8 / 7
2026-08-26	$-3.21	$13,900,000	7 / 7
2026-08-27	$-3.21	$13,900,000	7 / 7
2026-08-28	$-3.21	$13,900,000	7 / 7
2026-08-29	$-3.21	$13,900,000	8 / 7
2026-08-30	$-3.21	$13,900,000	8 / 7
2026-08-31	$-3.21	$13,900,000	8 / 7
2026-09-01	$-3.21	$13,900,000	8 / 7
2026-09-02	$-3.21	$13,900,000	8 / 7
2026-09-03	$-3.21	$13,900,000	8 / 7
2026-09-04	$-3.21	$13,900,000	8 / 7
2026-09-05	$-3.21	$13,900,000	8 / 7
2026-09-06	$-3.21	$13,900,000	8 / 7
2026-09-07	$-3.21	$13,900,000	8 / 7
2026-09-08	$-3.21	$13,900,000	8 / 7
2026-09-09	$-3.21	$13,900,000	8 / 7
2026-09-10	$-3.21	$13,900,000	8 / 7
2026-09-11	$-3.21	$13,900,000	8 / 7
2026-09-12	$-3.21	$13,900,000	8 / 7
2026-09-13	$-3.21	$13,900,000	8 / 7
2026-09-14	$-3.21	$13,900,000	8 / 7
2026-09-15	$-3.21	$13,900,000	8 / 7
2026-09-16	$-3.21	$13,900,000	8 / 7
2026-09-17	$-3.21	$13,900,000	8 / 7
2026-09-18	$-3.21	$13,900,000	8 / 7
2026-09-19	$-3.21	$13,900,000	8 / 7
2026-09-20	$-3.21	$13,900,000	8 / 7
2026-09-21	$-3.21	$13,900,000	8 / 7
2026-09-22	$-3.21	$13,900,000	8 / 7
2026-09-23	$-3.21	$13,900,000	8 / 7
2026-09-24	$-3.21	$13,900,000	8 / 7
2026-09-25	$-3.30	$12,162,500	8 / 8
2026-09-26	$-3.30	$12,162,500	8 / 8
2026-09-27	$-3.30	$12,162,500	8 / 8
2026-09-28	$-3.30	$12,162,500	8 / 8
2026-09-29	$-3.30	$12,162,500	8 / 8
2026-09-30	$-3.30	$12,162,500	8 / 8
2026-10-01	$-3.30	$12,162,500	8 / 8
2026-10-02	$-3.30	$12,162,500	8 / 8
2026-10-03	$-3.30	$12,162,500	8 / 8
2026-10-04	$-3.30	$12,162,500	8 / 8
2026-10-05	$-3.30	$12,162,500	8 / 8
2026-10-06	$-3.24	$12,162,500	8 / 8
2026-10-07	$-3.24	$12,162,500	8 / 8
2026-10-08	$-3.24	$12,162,500	8 / 8
2026-10-09	$-3.24	$12,162,500	8 / 8
2026-10-10	$-3.24	$12,162,500	8 / 8
2026-10-11	$-3.24	$12,162,500	8 / 8
2026-10-12	$-3.24	$12,162,500	8 / 8
2026-10-13	$-3.24	$12,162,500	8 / 8
2026-10-14	$-3.24	$12,162,500	8 / 8
2026-10-15	$-3.24	$12,162,500	8 / 8
2026-10-16	$-3.24	$12,162,500	8 / 8
2026-10-17	$-3.24	$12,162,500	8 / 8
2026-10-18	$-3.24	$12,162,500	8 / 8
2026-10-19	$-3.24	$12,162,500	8 / 8
2026-10-20	$-3.21	$12,162,500	8 / 8
2026-10-21	$-3.21	$10,811,111	8 / 8
2026-10-22	$-3.21	$10,811,111	8 / 9
2026-10-23	$-3.21	$10,811,111	8 / 9
2026-10-24	$-3.21	$10,811,111	9 / 9
2026-10-25	$-3.21	$10,811,111	9 / 9
2026-10-26	$-3.21	$10,811,111	9 / 9
2026-10-27	$-3.21	$10,811,111	9 / 9
2026-10-28	$-3.21	$10,811,111	9 / 9
2026-10-29	$-3.21	$10,811,111	9 / 9
2026-10-30	$-3.21	$10,811,111	9 / 9
2026-10-31	$-3.21	$10,811,111	9 / 9
2026-11-01	$-3.21	$10,811,111	9 / 9
2026-11-02	$-3.21	$10,811,111	9 / 9
2026-11-03	$-3.21	$10,811,111	9 / 9
2026-11-04	$-3.21	$10,811,111	9 / 9

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-06-01	12	0	0
2026-07-01	12	0	0
2026-08-01	12	0	0
2026-09-01	13	0	0
2026-10-01	14	0	0
2026-11-01	14	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 14 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Oct 6–Nov 4 · 0 recorded

What could strengthen or challenge Maze Therapeutics, Inc.’s outlook?

Price, analyst earnings & P/E reference

What the Thesis Depends On

Incoming Evidence

Expectations trend

Outlook in Brief

What's improving

Still unresolved / key risks

Next proof point

Historical risk context

Maze Therapeutics, Inc. outlook in detail

What kind of bet this is

What's priced into Maze Therapeutics, Inc.

What the fundamentals likely do

What Maze Therapeutics, Inc. hinges on

Bottom line

Analyst view

Price-target changes

Bottom line